{"id":402309,"date":"2020-12-17T16:08:34","date_gmt":"2020-12-17T21:08:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=402309"},"modified":"2020-12-17T16:08:34","modified_gmt":"2020-12-17T21:08:34","slug":"repare-therapeutics-added-to-the-nasdaq-biotechnology-index","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/","title":{"rendered":"Repare Therapeutics Added to the NASDAQ Biotechnology Index"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Repare Therapeutics Added to the NASDAQ Biotechnology Index<\/b><\/p>\n<p>CAMBRIDGE, Mass. &amp; MONTREAL&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRepare Therapeutics, Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index\u00ae (NASDAQ: ^NBI). Repare\u2019s addition to the NBI will become effective prior to market open on Monday, December 21, 2020.\n<\/p>\n<p>\nThe NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.\n<\/p>\n<p>\nFor more information about the NASDAQ Biotechnology Index, including eligibility criteria, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Findexes.nasdaqomx.com%2FIndex%2FOverview%2FNBI&amp;esheet=52350480&amp;newsitemid=20201217005830&amp;lan=en-US&amp;anchor=https%3A%2F%2Findexes.nasdaqomx.com%2FIndex%2FOverview%2FNBI&amp;index=1&amp;md5=e9e0c480ed9245b162337f3bcd62d645\">https:\/\/indexes.nasdaqomx.com\/Index\/Overview\/NBI<\/a>.\n<\/p>\n<p><b>About Repare Therapeutics, Inc.<\/b><\/p>\n<p>\nRepare Therapeutics is a leading clinical-state precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx\u00ae platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company\u2019s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Pol\u03b8 inhibitor programs. For more information, please visit reparerx.com.\n<\/p>\n<p>\nSNIPRx\u00ae is a registered trademark of Repare Therapeutics, Inc.\n<\/p>\n<p><b>Forward-Looking Statement<\/b><\/p>\n<p>\nThis press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are \u201cforward-looking statements. These statements may be identified by words such as \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cforecasts,\u201d \u201cgoal,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cseeks,\u201d \u201cwill\u201d and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the discovery of potential product candidates using SNIPRx\u00ae platform; and the clinical development of the Company\u2019s pipeline and its research and development programs, including the anticipated timing of its clinical trials of RP-3500 and RP-6306; and the development of preclinical assets pursuant to the Company\u2019s collaboration with Bristol Myers Squibb. These forward-looking statements are based on the Company\u2019s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company\u2019s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic on the Company\u2019s business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Company\u2019s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled &#8220;Risk Factors&#8221; in the Company\u2019s Quarterly Report on Form 10-Q for the period ended September 30, 2020 filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on November 12, 2020, and its subsequent filings with the SEC. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201217005830\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201217005830\/en\/<\/a><\/span><\/p>\n<p><b>Repare Contact:<\/b><\/p>\n<p>\nSteve Forte<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/>Repare Therapeutics, Inc.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:info@reparerx.com\">info@reparerx.com<\/a><\/p>\n<p><b>Investors:<\/b><\/p>\n<p>\nKimberly Minarovich<br \/>\n<br \/>Argot Partners<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:repare@argotpartners.com\">repare@argotpartners.com<\/a><\/p>\n<p><b>Media:<\/b><\/p>\n<p>\nDavid Rosen<br \/>\n<br \/>Argot Partners<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:david.rosen@argotpartners.com\">david.rosen@argotpartners.com<br \/>\n<\/a><br \/>212-600-1902\n<\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Genetics Pharmaceutical Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Repare Therapeutics Added to the NASDAQ Biotechnology Index CAMBRIDGE, Mass. &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; Repare Therapeutics, Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index\u00ae (NASDAQ: ^NBI). Repare\u2019s addition to the NBI will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is calculated under a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Repare Therapeutics Added to the NASDAQ Biotechnology Index&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-402309","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Repare Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Repare Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Repare Therapeutics Added to the NASDAQ Biotechnology Index CAMBRIDGE, Mass. &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; Repare Therapeutics, Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index\u00ae (NASDAQ: ^NBI). Repare\u2019s addition to the NBI will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is calculated under a &hellip; Continue reading &quot;Repare Therapeutics Added to the NASDAQ Biotechnology Index&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T21:08:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Repare Therapeutics Added to the NASDAQ Biotechnology Index\",\"datePublished\":\"2020-12-17T21:08:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/\"},\"wordCount\":721,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/\",\"name\":\"Repare Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-17T21:08:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Repare Therapeutics Added to the NASDAQ Biotechnology Index\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Repare Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/","og_locale":"en_US","og_type":"article","og_title":"Repare Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk","og_description":"Repare Therapeutics Added to the NASDAQ Biotechnology Index CAMBRIDGE, Mass. &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; Repare Therapeutics, Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index\u00ae (NASDAQ: ^NBI). Repare\u2019s addition to the NBI will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market\u00ae (NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is calculated under a &hellip; Continue reading \"Repare Therapeutics Added to the NASDAQ Biotechnology Index\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T21:08:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Repare Therapeutics Added to the NASDAQ Biotechnology Index","datePublished":"2020-12-17T21:08:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/"},"wordCount":721,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/","name":"Repare Therapeutics Added to the NASDAQ Biotechnology Index - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-17T21:08:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201217005830r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-added-to-the-nasdaq-biotechnology-index\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Repare Therapeutics Added to the NASDAQ Biotechnology Index"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/402309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=402309"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/402309\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=402309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=402309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=402309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}